1
|
Abreu MC, Conrad NL, Gonçalves VS, Leite FPL. Bacillus toyonensis amplifies the immunogenicity of an experimental recombinant tetanus vaccine in horses. J Equine Vet Sci 2024; 140:105135. [PMID: 38914241 DOI: 10.1016/j.jevs.2024.105135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Revised: 06/14/2024] [Accepted: 06/19/2024] [Indexed: 06/26/2024]
Abstract
Probiotic microorganisms can stimulate an immune response and increase the efficiency of vaccines. For example, Bacillus toyonensis is a nonpathogenic, Gram-positive bacterium that has been used as a probiotic in animal supplementation. It induces immunomodulatory effects and increases the vaccine response in several species. This study aimed to evaluate the effect of B. toyonensis supplementation on the modulation of the immune response in horses vaccinated with recombinant Clostridium tetani toxin. Twenty horses were vaccinated twice, with an interval of 21 days between doses, and equally divided into two groups: the first group was supplemented orally for 42 days with feed containing viable spores of B. toyonensis (1 × 108) mixed with molasses (40 ml), starting 7 days before the first vaccination; the second (control) group received only feed mixed with molasses, starting 7 days before the first vaccination. Serum samples were collected to evaluate the humoral immune response using an in-house indirect enzyme-linked immunosorbent assay (ELISA), and peripheral blood mononuclear cells (PBMCs) were collected to evaluate cytokine transcription (qPCR). For the specific IgG-anti-rTENT titer, the supplemented group had ELISA values that were four times higher than those of the control group (p < 0.05). The supplemented group also showed higher ELISA values for the IgGa and IgGT sub-isotypes compared to the control group. In PBMCs stimulated with B. toyonensis, relative cytokine transcription of the supplemented group showed 15-, 8-, 7-, and 6-fold increases for IL1, TNFα, IL10 and IL4, respectively. When stimulated with a vaccine antigen, the supplemented group showed 1.6-, 1.8-, and 0.5-fold increases in IL1, TNFα, and IL4, respectively, compared to the control group. Horses supplemented with B. toyonensis had a significantly improved vaccine immune response compared to those in the control group, which suggests a promising approach for improving vaccine efficacy with probiotics.
Collapse
Affiliation(s)
- Mayara Caetano Abreu
- Departament of Veterinary Medicine, Federal University of Pelotas, UFPel, Capão do Leão, Rio Grande do Sul, Brazil
| | - Neida Lucia Conrad
- Center for Technological Development, Biotecnology, Federal University of Pelotas, UFPel, Capão do Leão, Rio Grande do Sul, Brazil
| | - Vitória Sequeira Gonçalves
- Center for Technological Development, Biotecnology, Federal University of Pelotas, UFPel, Capão do Leão, Rio Grande do Sul, Brazil
| | - Fábio Pereira Leivas Leite
- Departament of Veterinary Medicine, Federal University of Pelotas, UFPel, Capão do Leão, Rio Grande do Sul, Brazil; Center for Technological Development, Biotecnology, Federal University of Pelotas, UFPel, Capão do Leão, Rio Grande do Sul, Brazil.
| |
Collapse
|
2
|
Moreira C, Rodrigues RR, da Cunha CEP, Donassolo RA, Ferreira MRA, Finger PF, Oliveira HGS, da Cruz KP, Moreira ÂN, Salvarani FM, Conceição FR. Evaluation of long-term immune response in cattle to botulism using a recombinant E. coli bacterin formulated with Montanide™ ISA 50 and aluminum hydroxide adjuvants. Microb Pathog 2024; 189:106596. [PMID: 38395317 DOI: 10.1016/j.micpath.2024.106596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 02/08/2024] [Accepted: 02/20/2024] [Indexed: 02/25/2024]
Abstract
Botulism is a severe disease caused by potent botulinum neurotoxins (BoNTs) produced by Clostridium botulinum. This disease is associated with high-lethality outbreaks in cattle, which have been linked to the ingestion of preformed BoNT serotypes C and D, emphasizing the need for effective vaccines. The potency of current commercial toxoids (formaldehyde-inactivated BoNTs) is assured through tests in guinea pigs according to government regulatory guidelines, but their short-term immunity raises concerns. Recombinant vaccines containing the receptor-binding domain have demonstrated potential for eliciting robust protective immunity. Previous studies have demonstrated the safety and effectiveness of recombinant E. coli bacterin, eliciting high titers of neutralizing antibodies against C. botulinum and C. perfringens in target animal species. In this study, neutralizing antibody titers in cattle and the long-term immune response against BoNT/C and D were used to assess the efficacy of the oil-based adjuvant compared with that of the aluminum hydroxide adjuvant in cattle. The vaccine formulation containing Montanide™ ISA 50 yielded significantly higher titers of neutralizing antibody against BoNT/C and D (8.64 IU/mL and 9.6 IU/mL, respectively) and induced an immune response that lasted longer than the response induced by aluminum, extending between 30 and 60 days. This approach represents a straightforward, cost-effective strategy for recombinant E. coli bacterin, enhancing both the magnitude and duration of the immune response to botulism.
Collapse
Affiliation(s)
- Clovis Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil.
| | - Rafael R Rodrigues
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Carlos E P da Cunha
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Rafael A Donassolo
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Marcos R A Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Paula F Finger
- Curso de Medicina Veterinária, Universidade Federal do Pampa, Uruguaiana, Rio Grande do Sul, CEP 97508-000, Brazil
| | - Hanna G S Oliveira
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Karoline P da Cruz
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Ângela N Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Felipe M Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Fabricio R Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| |
Collapse
|
3
|
Mbhele Z, Thwala L, Khoza T, Ramagoma F. Evaluation of Aluminium Hydroxide Nanoparticles as an Efficient Adjuvant to Potentiate the Immune Response against Clostridium botulinum Serotypes C and D Toxoid Vaccines. Vaccines (Basel) 2023; 11:1473. [PMID: 37766149 PMCID: PMC10535070 DOI: 10.3390/vaccines11091473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2023] [Revised: 08/26/2023] [Accepted: 09/08/2023] [Indexed: 09/29/2023] Open
Abstract
Clostridium botulinum serotypes C and D cause botulism in livestock, a neuroparalytic disease that results in substantial economic losses. Vaccination with aluminium-based toxoid vaccines is widely used to control the spread of botulism. Aluminium-based adjuvants are preferred owing to their apparent stimulation of the immune responses to toxoid vaccines when compared to other adjuvants. The aim of our study was to evaluate aluminium hydroxide nanoparticles as a potential substitute for alhydrogel in the botulism bivalent vaccine. Botulism vaccines were formulated with either alhydrogel or nanoalum and comparative efficacy between the two formulations was conducted by evaluating the immune response in vaccinated guinea pigs. A significant increase in immunological parameters was observed, with the antibody titres higher in the serum of guinea pigs (20 IU/mL of anti-BoNT C/D) injected with nanoalum-containing vaccine than guinea pigs inoculated with the standard alhydrogel-containing vaccine (8.7 IU/mL and 10 IU/mL of anti-BoNT C and anti-BoNT D, respectively). Additionally, the nanoalum-containing vaccine demonstrated potency in a multivalent vaccine (20 IU/mL of anti-BoNT C/D), while the standard alhydrogel-containing vaccine showed a decline in anti-BoNT C (5 IU/mL) antibody titres.
Collapse
Affiliation(s)
- Ziphezinhle Mbhele
- Onderstepoort Biological Products, 100 Old Soutpan Road, Onderstepoort, Pretoria 0110, South Africa; (Z.M.); (L.T.)
- Discipline of Biochemistry, School of Life Sciences, University of KwaZulu Natal, Pietermaritzburg Campus, Private Bag X01, Scottsville 3209, South Africa;
| | - Lungile Thwala
- Onderstepoort Biological Products, 100 Old Soutpan Road, Onderstepoort, Pretoria 0110, South Africa; (Z.M.); (L.T.)
- Council for Scientific and Industrial Research, National Laser Centre, Pretoria 0001, South Africa
| | - Thandeka Khoza
- Discipline of Biochemistry, School of Life Sciences, University of KwaZulu Natal, Pietermaritzburg Campus, Private Bag X01, Scottsville 3209, South Africa;
| | - Faranani Ramagoma
- Onderstepoort Biological Products, 100 Old Soutpan Road, Onderstepoort, Pretoria 0110, South Africa; (Z.M.); (L.T.)
| |
Collapse
|
4
|
Rodrigues Rodrigues R, Freitas Motta J, Alves Ferreira MR, Moreira Júnior C, Ferreira Alves ML, Costa AV, Andrade Bilhalva M, Amaral Donassolo R, Cancela Galvão C, Silva Martins FM, Masiero Salvarani F, Rochedo Conceição F. Immunization of sheep with a recombinant vaccine containing immunogenic nontoxic domains of Clostridium perfringens alpha and beta toxins. Microb Pathog 2023; 182:106269. [PMID: 37516212 DOI: 10.1016/j.micpath.2023.106269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2023] [Revised: 07/23/2023] [Accepted: 07/24/2023] [Indexed: 07/31/2023]
Abstract
Clostridium perfringens (types A and C) can cause several diseases by secreting alpha (CPA) and beta (CPB) exotoxins in the gastrointestinal tract. Although vaccination is the main measure of immunization against C. perfringens, available vaccines have limitations in terms of productivity and safety. Thus, recombinant vaccines are an important, more effective, practical, and safer strategy in the immunization of animals. In this study, we evaluated the immunization of sheep with recombinant Escherichia coli bacterins expressing CPA and CPB complete proteins (co-administered), the immunogenic nontoxic domains rCPA-C247-370 and rCPB-C143-311 co-administered or fused as a bivalent chimera (rCPBcAc). For this, in silico analysis was performed to design rCPBcAc, considering the stability of the mRNA (-278.80 kcal/mol), the degree of antigenicity (0.7557), the epitopes of the B cell ligand, and different physicochemical characteristics. All proteins were expressed in vitro. In vivo, animals vaccinated with the co-administered antigens rCPA + rCPB and rCPA-C+ rCPB-C (200 μg each) had mean CPA and CPB neutralizing antitoxin titers of 4, 10, 4.8, and 14.4 IU/mL, respectively, while those vaccinated with 200 μg of rCPBcAc chimera (approximately 100 μg of each antigen) had titers of <4 and 12 IU/mL of CPA and CPB antitoxins, respectively, 56 days after the administration of the first dose. In addition, the chimera was considered to be immunogenic for inducing antitoxin titers using the half dose. In this study, we presented a new recombinant antigen potentially applicable for vaccines against the CPA and CPB toxins for preventing diseases caused by Clostridium perfringens.
Collapse
Affiliation(s)
- Rafael Rodrigues Rodrigues
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil.
| | - Jaqueline Freitas Motta
- Faculdade de Veterinária, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| | | | - Clóvis Moreira Júnior
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil
| | - Mariliana Luiza Ferreira Alves
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil; Instituto Federal Sul-rio-grandense, IFSul, Campus Pelotas, RS, Brazil
| | - Ana Vitória Costa
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil
| | - Miguel Andrade Bilhalva
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil
| | - Rafael Amaral Donassolo
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil
| | - Cleideanny Cancela Galvão
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil
| | | | | | - Fabricio Rochedo Conceição
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Brazil; Faculdade de Veterinária, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, Brazil
| |
Collapse
|
5
|
Recombinant Escherichia coli Cell Lysates as a Low-Cost Alternative for Vaccines Against Veterinary Clostridial Diseases. METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2022; 2411:105-115. [PMID: 34816401 DOI: 10.1007/978-1-0716-1888-2_6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
This chapter describes a practical, industry-friendly, and efficient vaccine protocol based on the use of Escherichia coli cell fractions (inclusion bodies or cell lysate supernatant) containing the recombinant antigen. This approach was characterized and evaluated in laboratory and farm animals by the seroneutralization assay in mice, thereby showing to be an excellent alternative to induce a protective immune response against clostridial diseases.
Collapse
|
6
|
Measurement over 1 Year of Neutralizing Antibodies in Cattle Immunized with Trivalent Vaccines Recombinant Alpha, Beta and Epsilon of Clostridium perfringens. Toxins (Basel) 2021; 13:toxins13090594. [PMID: 34564599 PMCID: PMC8470993 DOI: 10.3390/toxins13090594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 08/03/2021] [Accepted: 08/06/2021] [Indexed: 11/17/2022] Open
Abstract
The alpha (CPA), beta (CPB) and epsilon (ETX) toxins of Clostridium perfringens are responsible for causing diseases that are difficult to eradicate and have lethal potential in production animals. Vaccination of herds is still the best control strategy. Recombinant clostridial vaccines have shown good success at inducing neutralizing antibody titers and appear to be a viable alternative to the conventional production of commercial clostridial toxoids. Research is still needed on the longevity of the humoral immune response induced by recombinant proteins in immunized animals, preferably in target species. The objective of this study was to measure the humoral immune response of cattle immunized with trivalent vaccines containing the recombinant proteins alpha (rCPA), beta (rCPB) and epsilon (rETX) of C. perfringens produced in Escherichia coli at three different concentrations (100, 200, and 400 µg) of each protein for 12 months. The recombinant vaccines containing 200 (RV2) and 400 µg (RV3) yielded statistically similar results at 56 days. They performed better throughout the study period because they induced higher neutralizing antibody titers and were detectable for up to 150 and 180 days, respectively. Regarding industrial-scale production, RV2 would be the most economical and viable formulation as it achieved results similar to RV3 at half the concentration of recombinant proteins in its formulation. However, none of the vaccines tested induced the production of detectable antibody titers on day 365 of the experiment, the time of revaccination typically recommended in vaccination protocols. Thus, reiterating the need for research in the field of vaccinology to achieve greater longevity of the humoral immune response against these clostridial toxins in animals, in addition to the need to discuss the vaccine schedules and protocols adopted in cattle production.
Collapse
|
7
|
Freitas NFQR, Otaka DY, Galvão CC, de Almeida DM, Ferreira MRA, Moreira Júnior C, Hidalgo MMMH, Conceição FR, Salvarani FM. Humoral Immune Response Evaluation in Horses Vaccinated with Recombinant Clostridium perfringens Toxoids Alpha and Beta for 12 Months. Toxins (Basel) 2021; 13:566. [PMID: 34437437 PMCID: PMC8402361 DOI: 10.3390/toxins13080566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 07/16/2021] [Accepted: 07/19/2021] [Indexed: 11/23/2022] Open
Abstract
In horses, Clostridium perfringens is associated with acute and fatal enterocolitis, which is caused by a beta toxin (CPB), and myonecrosis, which is caused by an alpha toxin (CPA). Although the most effective way to prevent these diseases is through vaccination, specific clostridial vaccines for horses against C. perfringens are not widely available. The aim of this study was to pioneer the immunization of horses with three different concentrations (100, 200 and 400 µg) of C. perfringens recombinant alpha (rCPA) and beta (rCPB) proteins, as well as to evaluate the humoral immune response over 360 days. Recombinant toxoids were developed and applied to 50 horses on days 0 and 30. Those vaccines attempted to stimulate the production of alpha antitoxin (anti-CPA) and beta antitoxin (anti-CPB), in addition to becoming innocuous, stable and sterile. There was a reduction in the level of neutralizing anti-CPA and anti-CPB antibodies following the 60th day; therefore, the concentrations of 200 and 400 µg capable of inducing a detectable humoral immune response were not determined until day 180. In practical terms, 200 µg is possibly the ideal concentration for use in the veterinary industry's production of vaccines against the action of C. perfringens in equine species.
Collapse
Affiliation(s)
- Nayra F. Q. R. Freitas
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Denis Y. Otaka
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Cleideanny C. Galvão
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Dayane M. de Almeida
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| | - Marcos R. A. Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Clóvis Moreira Júnior
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Marina M. M. H. Hidalgo
- Faculdade de Veterinária, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil;
| | - Fabricio R. Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul CEP 96160-000, Brazil; (M.R.A.F.); (C.M.J.); (F.R.C.)
| | - Felipe M. Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal CEP 68740-970, Brazil; (N.F.Q.R.F.); (D.Y.O.); (C.C.G.); (D.M.d.A.)
| |
Collapse
|
8
|
Rodrigues RR, Alves Ferreira MR, Donassolo RA, Ferreira Alves ML, Motta JF, Junior CM, Salvarani FM, Moreira AN, Conceicao FR. Evaluation of the expression and immunogenicity of four versions of recombinant Clostridium perfringens beta toxin designed by bioinformatics tools. Anaerobe 2021; 69:102326. [PMID: 33508438 DOI: 10.1016/j.anaerobe.2021.102326] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2020] [Revised: 01/02/2021] [Accepted: 01/19/2021] [Indexed: 02/06/2023]
Abstract
Beta toxins (CPB) produced by Clostridium perfringens type B and C cause various diseases in animals, and the use of toxoids is an important prophylactic measure against such diseases. Promising recombinant toxoids have been developed recently. However, both soluble and insoluble proteins expressed in Escherichia coli can interfere with the production and immunogenicity of these antigens. In this context, bioinformatics tools have been used to design new versions of the beta toxin, and levels of expression and solubility were evaluated in different strains of E. coli. The immunogenicity in sheep was assessed using the molecule with the greatest potential that was selected on analyzing these results. In silico analyzes, greater mRNA stability (-169.70 kcal/mol), solubility (-0.755), and better tertiary structure (-0.12) were shown by rCPB-C. None of the strains of E. coli expressed rFH8-CPB, but a high level of expression and solubility was shown by rCPB-C. Higher levels of total and neutralizing anti-CPB antibodies were observed in sheep inoculated with bacterins containing rCPB-C. Thus, this study suggests that due to higher productivity of rCPB-C in E. coli and immunogenicity, it is considered as the most promising molecule for the production of a recombinant vaccine against diseases caused by the beta toxin produced by C. perfringens type B and C.
Collapse
Affiliation(s)
| | | | - Rafael Amaral Donassolo
- Centro de Desenvolvimento Tecnológico/Biotecnologia, Universidade Federal de Pelotas, RS, Brazil
| | - Mariliana Luiza Ferreira Alves
- Centro de Desenvolvimento Tecnológico/Biotecnologia, Universidade Federal de Pelotas, RS, Brazil; Instituto Federal Sul-rio-grandense, IFSul, Campus Pelotas, RS, Brazil
| | - Jaqueline Freitas Motta
- Centro de Desenvolvimento Tecnológico/Biotecnologia, Universidade Federal de Pelotas, RS, Brazil
| | - Clovis Moreira Junior
- Centro de Desenvolvimento Tecnológico/Biotecnologia, Universidade Federal de Pelotas, RS, Brazil
| | - Felipe Masiero Salvarani
- Instituto de Medicina Veterinária, Universidade Federal Do Pará, Castanhal, CEP 68740-970, Pará, Brazil
| | - Angela Nunes Moreira
- Centro de Desenvolvimento Tecnológico/Biotecnologia, Universidade Federal de Pelotas, RS, Brazil
| | | |
Collapse
|
9
|
Barros de Pinho R, de Oliveira Silva MT, Brenner G, Dié Alves MS, Azevedo V, Dias Portela R, Borsuk S. A novel approach for an immunogen against Corynebacterium pseudotuberculosis infection: An Escherichia coli bacterin expressing phospholipase D. Microb Pathog 2021; 151:104746. [PMID: 33485993 DOI: 10.1016/j.micpath.2021.104746] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 01/12/2021] [Accepted: 01/13/2021] [Indexed: 11/17/2022]
Abstract
Corynebacterium pseudotuberculosis is the causative agent of caseous lymphadenitis (CLA) in small ruminants. There is still needed an immunoprophylaxis model, which induces a protective and sustained immune response against the bacteria. In this study, we evaluated a recombinant Escherichia coli bacterin expressing the recombinant phospholipase D (rPLD) protein, the most relevant virulence factor of C. pseudotuberculosis, as a potential vaccine formulation. E. coli BL21 (DE3) Star strain was used for rPLD protein expression and was then inactivated by formaldehyde. Four groups with 10 Balb/c mice each were immunized twice within a 21 days interval: G1-control - 0.9% saline solution; G2- E. coli bacterin/pAE (naked plasmid); G3- E. coli bacterin/pAE/pld; G4-purified recombinant rPLD. Subsequently, the animals were challenged with a C. pseudotuberculosis virulent strain and evaluated for 40 days. The highest survival rate was observed for G3 with 40% protection, followed by 30% in the purified rPLD group (G4). These two groups also showed considerable IgG production when compared with the control group (G1). Also, a higher significant expression of interferon-γ was observed for the experimental groups G2, G3, and G4 when compared with a control group (G1) (p < 0.05). These results represent that a recombinant bacterin can be seen as a promising approach for vaccinal antigens against CLA, being possible to be used in association of different vaccine strategies.
Collapse
Affiliation(s)
- Rodrigo Barros de Pinho
- Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil
| | - Mara Thais de Oliveira Silva
- Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil
| | - Gabriel Brenner
- Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil
| | - Mirna Samara Dié Alves
- Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil
| | - Vasco Azevedo
- Laboratório de Genética Celular e Molecular, Instituto de Ciências Biológicas, UFMG, Belo Horizonte, MG, 31270-901, Brazil
| | - Ricardo Dias Portela
- Laboratório de Imunologia e Biologia Molecular, Instituto de Ciências da Saúde, UFBA, Salvador, BA, 40140-100, Brazil
| | - Sibele Borsuk
- Laboratório de Biotecnologia Infecto-Parasitária, Centro de Desenvolvimento Tecnológico, Biotecnologia, UFPel, Pelotas, RS, 96010-900, Brazil.
| |
Collapse
|
10
|
Donassolo RA, Ferreira MRA, Moreira C, Dos Santos LM, Griep E, Moreira GMSG, Rodrigues RR, Moreira ÂN, Conceição FR. Formaldehyde effects on kanamycin resistance gene of inactivated recombinant Escherichia coli vaccines. Biotechnol Lett 2020; 42:2223-2230. [PMID: 32500473 DOI: 10.1007/s10529-020-02929-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Accepted: 05/29/2020] [Indexed: 11/28/2022]
Abstract
OBJECTIVES Earlier studies have demonstrated the use of inactivated recombinant E. coli (bacterins), to protect against Clostridium spp. in vaccinated animals. These bacterins have a simpler, safer, and faster production process. However, these bacterins carry expression plasmids, containing antibiotic resistance gene, which could be assimilate accidentally by environmental microorganisms. Considering this, we aimed to impair this plasmids using formaldehyde at different concentrations. RESULTS This compound inactivated the highest density of cells in 24 h. KanR cassette amplification was found to be impaired with 0.8% for 24 h or 0.4% for 72 h. Upon electroporation, E. coli DH5α ultracompetent cells were unable to acquire the plasmids extracted from the bacterins after inactivation procedure. Formaldehyde-treated bacterins were incubated with other viable strains of E. coli, leading to no detectable gene transfer. CONCLUSIONS We found that this compound is effective as an inactivation agent. Here we demonstrate the biosafety involving antibiotic resistance gene of recombinant E. coli vaccines allowing to industrial production and animal application.
Collapse
Affiliation(s)
- Rafael A Donassolo
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil.
| | - Marcos Roberto A Ferreira
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| | - Clóvis Moreira
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| | - Lucas M Dos Santos
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| | - Emili Griep
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| | - Gustavo M S G Moreira
- Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie , Spielmannstr, Technische Universität Braunschweig, Braunschweig, Germany
| | - Rafael R Rodrigues
- Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie , Spielmannstr, Technische Universität Braunschweig, Braunschweig, Germany
| | - Ângela N Moreira
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| | - Fabricio R Conceição
- Centro de Desenvolvimento Tecnológico, Biotecnologia, Universidade Federal de Pelotas, Rio Grande do Sul, Pelotas, Brasil
| |
Collapse
|
11
|
Otaka DY, Barbosa JD, de Souza LA, Moreira C, Ferreira MRA, Donassolo RA, Conceição FR, Salvarani FM. Recombinant vaccine against botulism in buffaloes: Evaluation of the humoral immune response over 12 months. Anaerobe 2020; 63:102201. [PMID: 32247696 DOI: 10.1016/j.anaerobe.2020.102201] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 03/02/2020] [Accepted: 03/29/2020] [Indexed: 12/23/2022]
Abstract
Botulism is a neuroparalytic intoxication, usually fatal, caused by the botulinum toxins (BoNTs). Vaccination is the best-known strategy to prevent this disease in ruminants. Serotypes C and D and their variants CD and DC are the main types responsible for botulism in bovine and buffaloes in Brazil and cattle in Japan and Europe. Brazil has a herd of approximately 1.39 million buffaloes and is the largest producer in the Western world. This study aimed to assess the humoral immune response of buffaloes during the 12-month period after vaccination against BoNT serotypes C and D with a recombinant vaccine in three different concentrations (100, 200, and 400 μg) of non-purified recombinant proteins (Vrec) and also with a bivalent commercial toxoid (Vcom). Vrec400 was the best vaccine among those tested because it induced higher levels of antibodies and maintained higher levels of antibodies for the longest time, while Vrec200 could be considered the most cost-effective vaccine for large-scale production. None of the vaccines were able to promote continuous immunological protection within the timeframe proposed by the current Brazilian vaccination protocol. Further studies should focus on vaccine adjustments to ensure continued humoral protection against botulism.
Collapse
Affiliation(s)
- Denis Y Otaka
- Instituto de Medicina Veterinária, Universidade Federal do Pará, BR 316 Km 61, Saudade II, Cristo Redentor, Castanhal, 68740-910, PA, Brazil.
| | - José D Barbosa
- Instituto de Medicina Veterinária, Universidade Federal do Pará, BR 316 Km 61, Saudade II, Cristo Redentor, Castanhal, 68740-910, PA, Brazil.
| | - Loise A de Souza
- Instituto de Medicina Veterinária, Universidade Federal do Pará, BR 316 Km 61, Saudade II, Cristo Redentor, Castanhal, 68740-910, PA, Brazil.
| | - Clóvis Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, 96160-000, RS, Brazil.
| | - Marcos R A Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, 96160-000, RS, Brazil.
| | - Rafael A Donassolo
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, 96160-000, RS, Brazil.
| | - Fabrício R Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, 96160-000, RS, Brazil.
| | - Felipe M Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, BR 316 Km 61, Saudade II, Cristo Redentor, Castanhal, 68740-910, PA, Brazil.
| |
Collapse
|
12
|
Pohanka M. Botulinum Toxin as a Biological Warfare Agent: Poisoning, Diagnosis and Countermeasures. Mini Rev Med Chem 2020; 20:865-874. [PMID: 32108007 DOI: 10.2174/1389557520666200228105312] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 02/06/2020] [Accepted: 02/13/2020] [Indexed: 12/16/2022]
Abstract
Botulinum toxin is a neurotoxin produced by Clostridium botulinum and some other relative species. It causes a lethal disease called botulism. It can enter the body via infections by Clostridium (e.g. wound and children botulism) or by direct contact with the toxin or eating contaminated food (food-borne botulism). Botulinum toxin is also considered as a relevant biological warfare agent with an expected high number of causalities when misused for bioterrorist or military purposes. The current paper surveys the actual knowledge about botulinum toxin pathogenesis, the manifestation of poisoning, and current trends in diagnostics and therapeutics. Relevant and recent literature is summarized in this paper.
Collapse
Affiliation(s)
- Miroslav Pohanka
- Faculty of Military Health Sciences, University of Defense, Trebesska 1575, Hradec Kralove CZ-50001, Czech Republic
| |
Collapse
|
13
|
Moreira C, Ferreira MRA, Finger PF, Magalhães CG, Cunha CEP, Rodrigues RR, Otaka DY, Galvão CC, Salvarani FM, Moreira ÂN, Conceição FR. Protective efficacy of recombinant bacterin vaccine against botulism in cattle. Vaccine 2020; 38:2519-2526. [PMID: 32037222 DOI: 10.1016/j.vaccine.2020.01.089] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 12/18/2019] [Accepted: 01/29/2020] [Indexed: 12/11/2022]
Abstract
Botulism is a paralytic disease caused by the intoxication of neurotoxins produced by Clostridium botulinum. Among the seven immunologically distinct serotypes of neurotoxins (BoNTs A - G), serotypes C and D, or a chimeric fusion termed C/D or D/C, are responsible for animal botulism. The most effective way to prevent botulism in cattle is through vaccination; however, the commercially available vaccines produced by detoxification of native neurotoxins are time-consuming and hazardous. To overcome these drawbacks, a non-toxic recombinant vaccine was developed as an alternative. In this study, the recombinant protein vaccine was produced using an Escherichia coli cell-based system. The formaldehyde-inactivated E. coli is able to induce 7.45 ± 1.77 and 6.6 ± 1.28 IU/mL neutralizing mean titers against BoNTs C and D in cattle, respectively, determined by mouse neutralization bioassay, and was deemed protective by the Brazilian legislation. Moreover, when the levels of anti-BoNT/C and D were compared with those achieved by the recombinant purified vaccines, no significant statistical difference was observed. Cattle vaccinated with the commercial vaccine developed 1.33 and 3.33 IU/mL neutralizing mean titers against BoNT serotypes C and D, respectively. To the best of our knowledge, this study is the first report on recombinant E. coli bacterin vaccine against botulism. The vaccine was safe and effective in generating protective antibodies and, thus, represents an industry-friendly alternative for the prevention of cattle botulism.
Collapse
Affiliation(s)
- Clóvis Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Marcos R A Ferreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Paula F Finger
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Carolina G Magalhães
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Carlos E P Cunha
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Rafael R Rodrigues
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Denis Y Otaka
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Cleideanny C Galvão
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Felipe M Salvarani
- Instituto de Medicina Veterinária, Universidade Federal do Pará, Castanhal, Pará, CEP 68740-970, Brazil
| | - Ângela N Moreira
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil
| | - Fabricio R Conceição
- Centro de Desenvolvimento Tecnológico, Núcleo de Biotecnologia, Universidade Federal de Pelotas, Pelotas, Rio Grande do Sul, CEP 96160-000, Brazil.
| |
Collapse
|